LCD L33438: Octreotide Acetate for Injectable Suspension (Sandostatin® LAR Depot) — Palmetto GBA
Endocrinology
Government source· CMS / MACverify ↗HCPCS Level II code
J2353 — Injection, octreotide, depot form for intramuscular injection, 1 mg
HCPCS Level IIVerified Sep 19, 2026
Medicare payment
—
No national Medicare fee schedule we hold prices J2353 — the Physician Fee Schedule lists it with status indicator E (2026 file). CMS fee schedules ↗
Code definition
Code
J2353
Code system
HCPCS Level II
Full description
Injection, octreotide, depot form for intramuscular injection, 1 mg
Policy activity for HCPCS J2353
CLV Intelligence is tracking 1 policy change that cite HCPCS J2353 most recently on 2026-09-12, drawn from 1 LCD/NCD coverage update. The changes span Endocrinology.
- LCD/NCD coverage update
- 1
Counts reflect the source documents CLV has matched to HCPCS J2353 to date; each links to the government publication that is authoritative. Monitored daily from CMS, the Federal Register, and Medicare Administrative Contractor publications.
Recent policy changes matched to J2353
Matched to this code by CLV analysis of each policy. The linked source document is authoritative.
Audit documentation
Building an audit file that includes HCPCS J2353?
The Tripwire Audit Pack exports 12 months of single-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
See audit packs — $349One-time purchase · not a subscription
Get alerts when policy changes affect J2353
Free weekly digest — no subscription required.
Get the free 90-day policy snapshot for your specialty
Free — no account required
See what CLV monitors for your specialty
Get a free 90-day sample snapshot — a PDF of every CMS and MAC policy change we tracked for your specialty and jurisdiction in the last quarter. Delivered instantly.
90-day windowPDF sample reportInstant download
By downloading, you agree to receive related policy update emails. You can unsubscribe at any time. Privacy policy